Tiffany Padilla
Acute Care · Little Rock, ARNPI 1497765010
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,230, 4.3 times the $524 reported in 2022. Among acute care clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$861
- AstraZeneca$731
- Sanofi$547
- United Therapeutics Corporation$279
- Regeneron Healthcare Solutions, Inc.$219
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,87598%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 81 | $1,163 |
| Boehringer Ingelheim | 38 | $861 |
| AstraZeneca | 42 | $731 |
| Sanofi | 26 | $547 |
| United Therapeutics Corporation | 8 | $279 |
| Regeneron Healthcare Solutions, Inc. | 10 | $219 |
| Mallinckrodt Hospital Products Inc. | 10 | $215 |
| Insmed, Inc. | 9 | $205 |
| Baxter Healthcare | 7 | $167 |
| La Jolla Pharmaceutical Company | 7 | $165 |
| Harmony Biosciences LLC | 6 | $155 |
| Mylan Specialty L.p. | 7 | $155 |
| Merck | 7 | $143 |
| Verona Pharma, Inc. | 5 | $110 |
| Vifor Pharma, Inc. | 5 | $87 |
| Viatris Specialty LLC | 3 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Grifols USA, LLC | 3 | $69 |
| Electromed, Inc. | 2 | $68 |
| Philips North America LLC | 3 | $62 |
| Inogen, Inc. | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $49 |
| Intuitive Surgical | 1 | $46 |
| Amgen | 2 | $44 |
| Bayer | 1 | $22 |
| Pulmonx Corporation | 1 | $22 |
| Pfizer | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| 3b Medical, Inc. | 1 | $17 |
| Sandoz | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$5,971 in reported general payments places this provider in the 90th percentile of 321 acute care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 497 | $389,441 |
| OfevNintedanib Esylate | 24 | $305,815 |
| Dupixent PenDupilumab | 24 | $91,622 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 99 | $66,311 |
| NucalaMepolizumab | 14 | $60,032 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $45,058 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 78 | $37,740 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $35,699 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $13,396 |
| Spiriva RespimatTiotropium Bromide | 22 | $12,894 |
| DuleraMometasone/Formoterol | 14 | $8,072 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $6,947 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 253 | $6,496 |
| Arnuity ElliptaFluticasone Furoate | 21 | $4,970 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $3,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,163 | $527,881674 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $861 | $363,767116 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $731 | $79,707140 claims |
| MerckDulera | $143 | $8,07214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 321 acute care providers in Arkansas.
Other acute care in Little Rock
- Jill AveryLittle Rock$117K
- Lynn FrazierLittle Rock$106K
- Beverly BaxterLittle Rock$95K
- Diane GlendinningLittle Rock$26K
- Beth CrowderLittle Rock$25K
- Carmen Paniagua TorresLittle Rock$21K
- Shana KloskeLittle Rock$14K
- Debra BrentLittle Rock$9K
- Ginger HartLittle Rock$9K
- Holly TrottaLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.